experspadmin

Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Mantle Cell Lymphoma
Oncology

Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Mantle Cell Lymphoma

expert roundtables
By Anita Kumar, MD; Daniel O. Persky, MD; Julie M. Vose, MD, MBA, FASCO
Relapsed/Refractory Mantle Cell Lymphoma: Individualized Treatment Planning
Oncology

Relapsed/Refractory Mantle Cell Lymphoma: Individualized Treatment Planning

expert roundtables
By Anita Kumar, MD; Daniel O. Persky, MD; Julie M. Vose, MD, MBA, FASCO
Mantle Cell Lymphoma: Key Questions for Next‐Generation Clinical Trials
Oncology

Mantle Cell Lymphoma: Key Questions for Next‐Generation Clinical Trials

patient care perspectives
By Anita Kumar, MD
Role of 18F-FDG PET or PET/CT in Mantle Cell Lymphoma
Oncology

Role of 18F-FDG PET or PET/CT in Mantle Cell Lymphoma

clinical topic updates
By Julie M. Vose, MD, MBA, FASCO
Mantle Cell Lymphoma: Bridges to Cellular Immunotherapy
Oncology

Mantle Cell Lymphoma: Bridges to Cellular Immunotherapy

clinical topic updates
By Daniel O. Persky, MD
Load More